For personal use only

ASX RELEASE

Withdrawal of AGM Resolutions 2,4,6,7,8 and 9 From Notice of Meeting

Adelaide, Australia, 24 November 2021 – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the withdrawal of AGM Resolutions 2,4,6,7,8 and 9 from the Notice of Meeting.

- Resolution 2 deals with the re election as a Director of Mr Alex Sundich. Following the resignation from the Board of Mr Sundich this resolution is no longer required
- Resolution 4 deals with a refresh of the employee incentive plan. Following discussions with major shareholders it has become apparent that that there is insufficient support for this resolution.
- Resolution 6 to 9 deals with options to Directors. The Directors having received feedback from major stakeholders that there was insufficient support for these resolutions.

The withdrawal of these items of business does not affect the validity of the proxy form attached to the 2021 NOM or any proxy votes made.

This release dated 24 November 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company
Tom Spurling
Managing Director
Nova Eye Medical Limited
W +61 417 818 658
tspurling@nova-eye.com

Investors
Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

For personal use only

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com